Protein Microarray Autoantibody Profiling for Neurodegenerative Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and diagnosis for neurodegenerative diseases, particularly Alzheimer's disease and autism spectrum disorders, due to the complexity of identifying specific autoantibodies associated with these conditions.
Innovation Solution
A method involving the use of biological samples to detect neurodegenerative disease diagnostic autoantibodies through assays with autoantigens specific to these diseases, utilizing protein microarrays and immunocomplex formation detection techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional detection methods are used for neurodegenerative diseases, then the diagnostic process is simple, but the detection precision and ability to identify specific autoantibodies is insufficient
Solution Approach 1:
The patent segments the complex diagnostic process into multiple sequential steps: sample preparation, microarray hybridization, washing, and detection. Each step isolates specific functions to achieve high precision in identifying neurodegenerative disease-associated autoantibodies while managing overall system complexity through modular organization.
Solution Approach 2:
The patent introduces protein microarrays as an intermediary tool between the biological sample and the detection system. The microarray serves as a mediator that captures and concentrates specific autoantibodies, enabling precise detection through standardized readout methods while bridging the gap between complex biological samples and analytical instruments.
2Reliability
If comprehensive autoantibody profiling is performed to improve diagnosis accuracy, then the diagnostic reliability improves, but the time required for detection increases
Solution Approach 1:
The patent performs preliminary action by pre-preparing protein microarrays with organized arrays of potential autoantibody targets before patient sample analysis. This pre-organization of detection targets allows for comprehensive profiling without adding time to the actual diagnostic process, as the detection system is ready to simultaneously assess multiple antibodies in parallel.
Solution Approach 2:
The patent transitions from sequential single-antibody detection to parallel multi-antibody detection by organizing targets in a two-dimensional microarray format. This dimensional change enables comprehensive autoantibody profiling to occur simultaneously rather than sequentially, maintaining diagnostic reliability while dramatically reducing total detection time.
3Measurement precision
If specific autoantibody detection is implemented to improve diagnostic accuracy, then the measurement precision improves, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent creates a universal detection platform using protein microarrays that can simultaneously detect multiple different autoantibodies associated with various neurodegenerative diseases. This multi-functional system addresses the difficulty of detecting specific autoantibodies by providing a standardized, reusable platform that handles diverse targets through consistent procedures and readout methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and diagnosis of neurodegenerative diseases by identifying specific autoantibodies, providing a subject-specific profile for risk assessment and disease diagnosis.
Implementation Method 1
utilizing protein microarrays and immunocomplex formation detection techniques
Data Source
AI summary
The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles.